RxDoctor Payments DataLook up a doctor →

Yen-Yi Peng, MD

Neurology · Reno, NVNPI 1891951638

Payments from drug & device makers

$13,727in general payments, 2019–2025

Across 734 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$1K
  • SK Life Science, Inc.$768
  • Biogen$761
  • Novartis$671
  • plus $8K from 52 others

What the payments were for

  • Speaking & faculty fees$440%
  • Food & beverage$13,49698%
  • Education$1871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.95$1,527
AbbVie(2 entities)82$1,270
Neurocrine Biosciences, Inc.34$1,020
SK Life Science, Inc.44$768
Biogen52$761
Novartis40$671
EMD Serono, Inc.25$638
Pfizer42$602
MDD US Operations, LLC23$531
Teva Pharmaceuticals USA, Inc.35$526
Sanofi25$505
Amneal Pharmaceuticals LLC19$397
Argenx US, Inc.12$369
Kyowa Kirin, Inc.13$332
Bristol Myers Squibb17$286
Johnson & Johnson(2 entities)15$223
Acadia Pharmaceuticals Inc11$204
Takeda Pharmaceuticals U.S.A., Inc.9$198
Greenwich Biosciences, Inc.4$189
Lundbeck LLC9$186
AstraZeneca9$183
Amgen(2 entities)9$181
Sunovion Pharmaceuticals Inc.11$168
Neurelis, Inc.7$140
Eisai Inc.7$136
Aquestive Therapeutics, Inc.3$136
Octapharma USA, Inc.6$130
Genentech USA, Inc.5$110
Jazz Pharmaceuticals Inc.4$108
Impel Pharmaceuticals Inc.6$105
Otsuka America Pharmaceutical, Inc.4$95
Lilly USA, LLC5$86
CSL Behring4$78
Merz Pharmaceuticals, LLC3$74
Sumitomo Pharma America, Inc.4$70
ANI Pharmaceuticals, Inc.3$67
Tanabe Pharma America, Inc.3$56
Scilex Pharmaceuticals Inc.3$56
Acorda Therapeutics, Inc2$44
Biohaven Pharmaceuticals, Inc.3$42
Grifols USA, LLC2$39
Supernus Pharmaceuticals, Inc.3$37
GE HealthCare2$37
Xeris Pharmaceuticals, Inc.2$35
Adamas Pharmaceuticals, Inc.2$33
Catalyst Pharmaceuticals, Inc.2$31
Boston Scientific2$31
Otsuka Pharmaceutical Development & Commercialization, Inc.1$27
Axsome Therapeutics, Inc.1$26
Banner Life Sciences, LLC2$26
Livanova USA, Inc.1$22
Cala Health, Inc.1$20
Avanir Pharmaceuticals, Inc.1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Sanofi-aventis U.S. LLC1$16
Averitas Pharma Inc.1$15
Zyla Life Sciences, Inc.1$14
Merz North America, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,727 in reported general payments places this provider in the 70th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$248,980
Medicare patients
484
Services billed
1,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5016$229,144
XcopriCenobamate92$169,283
AptiomEslicarbazepine Acetate32$69,938
BriviactBrivaracetam26$68,628
GocovriAmantadine Hcl18$59,149
RytaryCarbidopa/Levodopa25$39,761
BotoxOnabotulinumtoxina24$34,343
Lacosamide146$32,609
Nurtec OdtRimegepant Sulfate14$20,975
Memantine Hcl501$18,746
Emgality PenGalcanezumab-Gnlm14$16,925
FycompaPerampanel12$14,379
Carbidopa-LevodopaCarbidopa/Levodopa275$12,702
Zonisamide272$11,130
Levetiracetam287$9,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$78$229,14416 claims
SK Life Science, Inc.Xcopri$768$169,28392 claims
Sunovion Pharmaceuticals Inc.Aptiom$168$69,93832 claims
UCB, Inc.Briviact$1,527$68,62826 claims
MDD US Operations, LLCGocovri$531$59,14918 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$397$42,50664 claims
AbbVieBotox$1,270$34,34324 claims
PfizerNurtec Odt$602$20,97514 claims
Eisai Inc.Fycompa$136$14,37912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 145 neurology providers in Nevada.

Other neurology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →